Diabetes Innovation
For the Rest of Us
At Modular Medical, we are dedicated to helping people with diabetes effectively manage their care more easily, by leveraging user friendly technology across cost-effective solutions.
“…you really want an insulin pump
to simplify insulin delivery,
not make it more complicated…”
Virginia Valentine, APRN, BC-ADM, CDCES, FADCES*
Clinical Nurse Specialist - Diabetes
Clinica La Esperanza, Albuquerque, New Mexico
Market Challenge:
While Pumps Improve Glycemic Control,1-4
2 in 3 of People with Type 1 Diabetes Still
Manually Inject Insulin5
Diabetes and Glycemic Control
Tens of thousands of people suffer annually from the complications of diabetes, such as cardiovascular events, neuropathy, dementia, kidney disease, blindness and lower limb amputation – frequent consequences of poorly managed glycemic control.6,7,8
Lowering A1c values, which are a measure of blood glucose over a period of 3 months, reduces the risks associated with adverse clinical outcomes.9 However, achievement of glycemic targets did not improve as shown in a recent 5-year trend analysis and, in fact, worsened.8
Average A1c
2010–2012 vs. 2016–2018
Adults by Age8
Individuals with > 3 years of A1c data
†Pooled data
Insulin Pumps
Insulin pumps facilitate insulin delivery and, when used regularly, are proven to improve glycemic control, reduce A1c levels, and improve quality of life in people with diabetes.1-4,10
Despite over a decade of claimed advances in insulin delivery technology, only a minority of individuals with Type 1 diabetes use a pump.
Only 1 in 3 people
with T1D use an insulin pump5
Type 1 Diabetes
(1.5 million people)11
2 in 3 rely on MDI
“Insulin pump therapy was introduced over
30 years ago, and it is somewhat
surprising to see how poor the penetrance
has been for this treatment.”
Dr. Pratik Choudhary
Diabetes Research Group
King’s College London, United Kingdom
Why Don’t More People Use Insulin Pumps?
Time
Money
Technology
Today, insulin-requiring people with diabetes must invest significant time to manage therapy, cover high out-of-pocket expenses, and operate complicated “advanced” pump systems. However, for the rest of us, access to these important technologies may be prohibitive, their use too difficult, and the infringement on lifestyle too great — multiple daily injections have been the only practical solution.
It’s Time to Change This
Type 1 Diabetes
(1.5 million people)11
30% of those using MDI are
“almost pumpers” — they would use an
insulin pump IF it required…
less time, expense and technical know-how than current pump technology.12
For the 300,000 “almost pumpers”
that want an easier relationship with their diabetes technology…
We have a solution.
“The future of diabetes management
is about device flexibility
and interoperability - areas where
Modular Medical is clearly setting the trend.”
Gary Scheiner, MS, CDCES*
Owner & Clinical Director
Integrated Diabetes Services LLC, Wynnewood, PA
Modular Medical is focused on
alternatives for individuals with
Type 1 diabetes that encourage adoption of
simplified insulin delivery technology
Our solutions intend to:
- Simplify the diabetes management experience
- Be easy to learn and intuitive to use
- Improve access to diabetes technologies that improve outcomes1-3
- Require less time for diabetes management and allow more time for what’s important
Our Mission
At Modular Medical, our mission is to deliver innovative technologies that simplify diabetes management.
Our Vision
We aspire to expand access to diabetes technology that liberates and empowers people to improve their health and well-being.
About Us: Management Team
Paul DiPerna
Founder, CEO and President
Steve Daly
Chief Commercial Officer
Paul DiPerna
Founder, CEO and President
Paul leads the Modular Medical organization. He possesses over 30 years of experience in the medical device industry as a technologist, business executive and founder of several successful startups. He has been deeply involved in Diabetes care for the past 20 years.
Paul’s early background includes key roles at Baxter Healthcare where he worked in cell separation product design, high volume manufacturing, business development, initial startups to evaluate technology within the spaces between divisions, corporate project management and technical diligence on acquisitions. Upon leaving Baxter in 2003, Paul founded, created the technology, and was CEO and board member for a diabetes delivery innovation that became Tandem Diabetes Care (TNDM, $450M IPO in 2013). Paul also co-invented the Ivera Medical blood-borne infection control device technology and provided guidance through the company’s successful $150M exit to 3M in 2015. During the transition, Paul assisted in production enhancements, refining product performance and intellectual property that led to demonstrated reductions in blood-borne infections and nurse compliance.
In 2015, Paul founded what is now Modular Medical, an initially self-funded diabetes delivery technology company that merged into a financed public shell in 2017. At Modular Medical, Paul’s focus is on the use of disruptive micro pumping technology and a simplified user experience for those less able and motivated to manage diabetes using current technologies.
Paul has serves on several boards to help guide many early stage startups. Paul received a Bachelor of Science in Mechanical Engineering from the University of Massachusetts and a Master’s in Engineering Management from Northeastern University. Mr. DiPerna holds over 70 patents, primarily in blood separation technologies, micro pumping and systems for the care of diabetes.
Steve Daly
Chief Commercial Officer
Steve leads the commercialization of Modular Medical’s novel and innovative insulin delivery technology. With much of his experience centered around diabetes care, Steve brings more than 25 years of experience in therapeutic product and device development and commercialization to direct the company’s strategy, business development and partnering activities.
Prior to joining the Modular Medical team, Steve has held multiple executive and marketing leadership positions with Adocia, Halozyme Therapeutics and Amylin Pharmaceuticals. His experience is peppered with a demonstrated record of successful strategic partnerships including for BioChaperone® Lispro (Eli Lilly) and Omontys® (Takeda), as well as commercial product introductions and brand management of Hylenex®, SYMLIN® and many others. His leadership across multiple cross-functional teams, brand development and execution strategies have contributed to exponential revenue growth, global partnerships and business expansion. In addition, Steve has received numerous awards for best practices in alliance teamwork, evidence-based and cross-functional brand team methodologies and facilitative leadership.
Steve holds a Bachelor of Science degree in Business Administration from Northeastern University and a Master of Business Administration from the University of Florida